Triple Drug Combo Clears Aging Cells and Cancer While Extending Mouse Lifespan

Two of the most formidable challenges in aging biology — cellular senescence and cancer — share a surprising commonality: dysfunctional energy metabolism. A new study from UC Berkeley's Conboy Lab proposes exploiting this overlap with a novel drug combination that selectively destroys both cell types while sparing healthy tissue.

The researchers focused on Navitoclax (ABT-263), a BCL-2 family inhibitor with proven senolytic and antitumor activity. Its clinical use has been hampered by dose-dependent thrombocytopenia — dangerous platelet depletion — and resistance in some tumor types. To circumvent this, they combined Navitoclax at one-tenth its standard dose with dichloroacetate (DCA), a pyruvate dehydrogenase kinase inhibitor that pushes cells toward oxidative metabolism, and metformin, a widely used diabetes drug that inhibits mitochondrial complex I. The combination is referred to as DMA.

In vitro, DMA successfully ablated multiple senescent and cancer cell types by amplifying their pre-existing defects in ATP production. Crucially, healthy human cells tolerated the treatment well, suggesting a meaningful therapeutic window based on metabolic differences between normal and dysfunctional cells.

In mouse studies, acute DMA administration improved functional performance in aged animals, while prolonged treatment extended lifespan — a significant finding given how few interventions demonstrate lifespan extension starting in old animals. The data suggest DMA acts through metabolic rather than purely cytotoxic mechanisms.

Caveats remain. The study relies on an abstract, meaning full mechanistic data, dosing protocols, lifespan curves, and safety profiles await peer-reviewed publication details. The translation from mouse models to human aging and oncology contexts is complex. Still, DMA represents a potentially accessible and repurposed-drug-based strategy that warrants serious further investigation.